Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prestige Brands Chloraseptic $4 Mil. TV Ad Campaign Debuting In October

This article was originally published in The Tan Sheet

Executive Summary

Prestige Brands International is backing its Chloraseptic brand with more than $4 mil. in TV advertising that will introduce a new sore throat spray formulated specifically for children.

You may also be interested in...



Chloraseptic

P&G divests throat spray line to Prestige Brands International. The deal was struck in March but not publicized, Bonita Springs, Fla.-based Prestige says. The move is in line with P&G's brand refocusing strategy, in which the company plans to support its top 10 brands and divest less profitable lines (1"The Tan Sheet" Aug. 7, p. 8). P&G also is seeking a buyer for its Clearasil acne products (2"The Tan Sheet" Aug. 28, In Brief). Prestige's only other product is Prell shampoo, which it bought from P&G last November; it was the first in what the firm says will be a series of brand acquisitions. Chloraseptic will continue to be manufactured by P&G, Prestige notes

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092989

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel